Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/28/23
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 01/05/24
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 02/25/25
End: 08/01/27
Due: 08/01/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | NCT05954312 | Vividion Therapeutics, Inc. | user2@example.com | None | 2023-07-28 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | NCT06188208 | Vividion Therapeutics, Inc. | user2@example.com | None | 2024-01-05 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | NCT06804824 | Vividion Therapeutics, Inc. | user2@example.com | None | 2025-02-25 | 2027-08-01 | 2028-08-01 | - | - | 2025-07-14 |